Australia's system of HTA decision-making can be imagined as a scramble of one hundred eggs. For the therapies and other technologies that provide better patient outcomes, the review's report proposes adding more eggs to the scramble. For therapies that can deliver savings, the scramble is discarded.
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News
